Literature DB >> 31524720

Status epilepticus - time is brain and treatment considerations.

Caroline Der-Nigoghossian1, Clio Rubinos2, Ayham Alkhachroum2, Jan Claassen2.   

Abstract

PURPOSE OF REVIEW: Status epilepticus is a neurological emergency associated with high morbidity and mortality. There is a lack of robust data to guide the management of this neurological emergency beyond the initial treatment. This review examines recent literature on treatment considerations including the choice of continuous anesthetics or adjunctive anticonvulsant, the cause of the status epilepticus, and use of nonpharmacologic therapies. RECENT
FINDINGS: Status epilepticus remains undertreated and mortality persists to be unchanged over the past 30 years. New anticonvulsant choices, such as levetiracetam and lacosamide have been explored as alternative emergent therapies. Anecdotal reports on the use of other generation anticonvulsants and nonpharmacologic therapies for the treatment of refractory and super-refractory status epilepticus have been described.Finally, recent evidence has examined etiology-guided management of status epilepticus in certain patient populations, such as immune-mediated, paraneoplastic or infectious encephalitis and anoxic brain injury.
SUMMARY: Randomized clinical trials are needed to determine the role for newer generation anticonvulsants and nonpharmacologic modalities for the treatment of epilepticus remains and evaluate the long-term outcomes associated with continuous anesthetics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31524720      PMCID: PMC7881804          DOI: 10.1097/MCC.0000000000000661

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  63 in total

1.  High-dose midazolam infusion for refractory status epilepticus.

Authors:  Andres Fernandez; Hector Lantigua; Christine Lesch; Belinda Shao; Brandon Foreman; J Michael Schmidt; Lawrence J Hirsch; Stephan A Mayer; Jan Claassen
Journal:  Neurology       Date:  2013-12-20       Impact factor: 9.910

2.  Intramuscular versus intravenous therapy for prehospital status epilepticus.

Authors:  Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

3.  Acute Resective Surgery for the Treatment of Refractory Status Epilepticus.

Authors:  Maysaa Merhi Basha; Kushak Suchdev; Monica Dhakar; William J Kupsky; Sandeep Mittal; Aashit K Shah
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

4.  Duration of therapeutic coma and outcome of refractory status epilepticus.

Authors:  Wolfgang G Muhlhofer; Stephen Layfield; Daniel Lowenstein; Chee Paul Lin; Robert D Johnson; Shalini Saini; Jerzy P Szaflarski
Journal:  Epilepsia       Date:  2019-04-07       Impact factor: 5.864

5.  Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.

Authors:  Stuart R Dalziel; Meredith L Borland; Jeremy Furyk; Megan Bonisch; Jocelyn Neutze; Susan Donath; Kate L Francis; Cynthia Sharpe; A Simon Harvey; Andrew Davidson; Simon Craig; Natalie Phillips; Shane George; Arjun Rao; Nicholas Cheng; Michael Zhang; Amit Kochar; Christine Brabyn; Ed Oakley; Franz E Babl
Journal:  Lancet       Date:  2019-04-17       Impact factor: 79.321

6.  Acute brain failure in severe sepsis: a prospective study in the medical intensive care unit utilizing continuous EEG monitoring.

Authors:  Emily J Gilmore; Nicolas Gaspard; Huimahn A Choi; Emily Cohen; Kristin M Burkart; David H Chong; Jan Claassen; Lawrence J Hirsch
Journal:  Intensive Care Med       Date:  2015-03-13       Impact factor: 17.440

7.  Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane.

Authors:  Seyed M Mirsattari; Michael D Sharpe; G Bryan Young
Journal:  Arch Neurol       Date:  2004-08

Review 8.  Newer Antiepileptic Drugs for Status Epilepticus in Adults: What's the Evidence?

Authors:  Isabelle Beuchat; Jan Novy; Andrea O Rossetti
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 9.  Cefepime-induced neurotoxicity: a systematic review.

Authors:  Lauren E Payne; David J Gagnon; Richard R Riker; David B Seder; Elizabeth K Glisic; Jane G Morris; Gilles L Fraser
Journal:  Crit Care       Date:  2017-11-14       Impact factor: 9.097

10.  Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.

Authors:  Mark D Lyttle; Naomi E A Rainford; Carrol Gamble; Shrouk Messahel; Amy Humphreys; Helen Hickey; Kerry Woolfall; Louise Roper; Joanne Noblet; Elizabeth D Lee; Sarah Potter; Paul Tate; Anand Iyer; Vicki Evans; Richard E Appleton
Journal:  Lancet       Date:  2019-04-17       Impact factor: 79.321

View more
  3 in total

1.  Factors affecting prognosis of status epilepticus among patients presenting to a tertiary care hospital.

Authors:  Wajid Jawaid; Muhammad Irfan; Sundus Mehtab Shafee; Sidra Javed Barry; Sayed Mustafa Mahmood Shah; Naila Shahbaz
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

Review 2.  Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.

Authors:  Adam Strzelczyk; Laurent M Willems; Ricardo Kienitz; Lara Kay; Isabelle Beuchat; Sarah Gelhard; Sophie von Brauchitsch; Catrin Mann; Alexandra Lucaciu; Jan-Hendrik Schäfer; Kai Siebenbrodt; Johann-Philipp Zöllner; Susanne Schubert-Bast; Felix Rosenow
Journal:  CNS Drugs       Date:  2022-08-16       Impact factor: 6.497

Review 3.  [Pharmacotherapy and intensive care aspects of status epilepticus: update 2020/2021].

Authors:  Gabrielė Saitov; Annekatrin Müller; Börge Bastian; Dominik Michalski
Journal:  Anaesthesist       Date:  2021-07-01       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.